Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.

Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G.

Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0623-5. [Epub ahead of print]

PMID:
31719677
2.

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.

Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N.

Br J Haematol. 2019 Nov;187(4):543-545. doi: 10.1111/bjh.16245. Epub 2019 Oct 4. No abstract available.

PMID:
31584727
3.

Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders.

Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H.

Haematologica. 2019 Sep 26. pii: haematol.2019.229583. doi: 10.3324/haematol.2019.229583. [Epub ahead of print]

4.

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2019 Sep 25. doi: 10.1002/cncr.32504. [Epub ahead of print]

PMID:
31553487
5.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.

PMID:
31310323
6.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Jun 27:1-4. doi: 10.1080/10428194.2019.1633635. [Epub ahead of print] No abstract available.

PMID:
31246142
7.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
8.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 Sep 15;125(18):3219-3224. doi: 10.1002/cncr.32196. Epub 2019 May 31.

PMID:
31150121
9.

FLT3 inhibitor quizartinib (AC220).

Naqvi K, Ravandi F.

Leuk Lymphoma. 2019 Aug;60(8):1866-1876. doi: 10.1080/10428194.2019.1602263. Epub 2019 Apr 18.

PMID:
30997851
10.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
11.

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.

Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G.

Cancer. 2019 Mar 12. doi: 10.1002/cncr.32056. [Epub ahead of print]

PMID:
30861111
12.

Hematologic malignancies and Li-Fraumeni syndrome.

Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD.

Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1). pii: a003210. doi: 10.1101/mcs.a003210. Print 2019 Feb.

13.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):142-148.e1. doi: 10.1016/j.clml.2018.12.009. Epub 2018 Dec 20.

PMID:
30635233
14.

Predictors of sleep hypoxemia in children with cystic fibrosis.

Isaiah A, Daher A, Sharma PB, Naqvi K, Mitchell RB.

Pediatr Pulmonol. 2019 Mar;54(3):273-279. doi: 10.1002/ppul.24233. Epub 2019 Jan 4.

PMID:
30609295
15.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F.

Cancer. 2019 Apr 1;125(7):1091-1100. doi: 10.1002/cncr.31885. Epub 2018 Dec 6.

PMID:
30521114
16.

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.

Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15.

PMID:
30328139
17.

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.

Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

18.

Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

Naqvi K, Kantarjian HM.

Cancer. 2018 Nov 1;124(21):4261. doi: 10.1002/cncr.31683. Epub 2018 Oct 1. No abstract available.

19.

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2018 Jul 1;124(13):2740-2747. doi: 10.1002/cncr.31357. Epub 2018 May 3.

20.

An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL).

Khan M, Siddiqi R, Naqvi K.

Ann Hematol. 2018 Jun;97(6):945-953. doi: 10.1007/s00277-018-3297-6. Epub 2018 Mar 15. Review.

PMID:
29546454
21.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.

Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H.

Int J Hematol. 2018 Jun;107(6):689-695. doi: 10.1007/s12185-018-2422-6. Epub 2018 Feb 20.

PMID:
29464484
22.

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P.

Clin Case Rep. 2017 Dec 6;6(1):155-161. doi: 10.1002/ccr3.1264. eCollection 2018 Jan.

23.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.

Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD.

Int J Mol Sci. 2017 Jul 26;18(8). pii: E1618. doi: 10.3390/ijms18081618.

24.

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F.

Leukemia. 2018 Jan;32(1):241-244. doi: 10.1038/leu.2017.285. Epub 2017 Sep 18. No abstract available.

PMID:
28919634
25.

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

Naqvi K, Konopleva M, Ravandi F.

Expert Rev Hematol. 2017 Oct;10(10):863-874. doi: 10.1080/17474086.2017.1366852. Epub 2017 Aug 21. Review.

PMID:
28799432
26.

Extensive ulcerated lesions in a patient with cutaneous myeloid sarcoma responded to twice-daily fludarabine and cytarabine regimen.

Khan M, Siddiqi R, Curry JL, Naqvi K.

Blood Cells Mol Dis. 2018 Mar;69:43-44. doi: 10.1016/j.bcmd.2017.05.012. Epub 2017 May 24. No abstract available.

PMID:
28624256
27.

Very Severe Obstructive Sleep Apnea in Children: Outcomes of Adenotonsillectomy and Risk Factors for Persistence.

Isaiah A, Hamdan H, Johnson RF, Naqvi K, Mitchell RB.

Otolaryngol Head Neck Surg. 2017 Jul;157(1):128-134. doi: 10.1177/0194599817700370. Epub 2017 Apr 11.

PMID:
28397574
28.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G.

Leukemia. 2017 Jul;31(7):1659. doi: 10.1038/leu.2017.85. Epub 2017 Mar 24.

PMID:
28338082
29.

Mechanistic insights into the bleaching of melanin by alkaline hydrogen peroxide.

Smith RAW, Garrett B, Naqvi KR, Fülöp A, Godfrey SP, Marsh JM, Chechik V.

Free Radic Biol Med. 2017 Jul;108:110-117. doi: 10.1016/j.freeradbiomed.2017.03.014. Epub 2017 Mar 18.

PMID:
28323131
30.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G.

Leukemia. 2017 Feb;31(2):318-324. doi: 10.1038/leu.2016.303. Epub 2016 Oct 31. Erratum in: Leukemia. 2017 Jul;31(7):1659.

PMID:
27795561
31.

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2017 Apr;58(4):866-871. doi: 10.1080/10428194.2016.1217528. Epub 2016 Aug 5.

32.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M.

Am J Hematol. 2016 Dec;91(12):1221-1226. doi: 10.1002/ajh.24500. Epub 2016 Aug 29.

33.

Corrigendum to Fluorescence and phosphorescence of tryptophan in peptides of different length and sequence [J. Photochem. Photobiol., B Vol. 157, April 2016, Pages 120-128].

Radotić K, Melø TB, Leblanc RM, Yousef YA, Naqvi KR.

J Photochem Photobiol B. 2016 May;158:281. doi: 10.1016/j.jphotobiol.2016.03.034. Epub 2016 Apr 8. No abstract available.

PMID:
27066859
34.

Identification and Partial Characterization of a Novel UDP-N-Acetylenolpyruvoylglucosamine Reductase/UDP-N-Acetylmuramate:l-Alanine Ligase Fusion Enzyme from Verrucomicrobium spinosum DSM 4136(T).

Naqvi KF, Patin D, Wheatley MS, Savka MA, Dobson RC, Gan HM, Barreteau H, Blanot D, Mengin-Lecreulx D, Hudson AO.

Front Microbiol. 2016 Mar 23;7:362. doi: 10.3389/fmicb.2016.00362. eCollection 2016.

35.

Fluorescence and phosphorescence of tryptophan in peptides of different length and sequence.

Radotić K, Melø TB, Leblanc RM, Yousef YA, Naqvi KR.

J Photochem Photobiol B. 2016 Apr;157:120-8. doi: 10.1016/j.jphotobiol.2016.02.011. Epub 2016 Feb 15.

PMID:
26916609
36.

Least-Squares Is Not the Only Yardstick for Estimating the Absorption Limit of an Infinitely Long Conjugated Chain from Spectra of Oligomers.

Naqvi KR.

J Phys Chem Lett. 2016 Feb 18;7(4):676-9. doi: 10.1021/acs.jpclett.6b00060. No abstract available.

PMID:
26888343
37.

Cloning, expression, purification, crystallization and X-ray diffraction analysis of dihydrodipicolinate synthase from the human pathogenic bacterium Bartonella henselae strain Houston-1 at 2.1 Å resolution.

Naqvi KF, Staker BL, Dobson RC, Serbzhinskiy D, Sankaran B, Myler PJ, Hudson AO.

Acta Crystallogr F Struct Biol Commun. 2016 Jan;72(Pt 1):2-9. doi: 10.1107/S2053230X15023213. Epub 2016 Jan 1.

38.

Whole-Genome Sequencing and Annotation of Bacillus safensis RIT372 and Pseudomonas oryzihabitans RIT370 from Capsicum annuum (Bird's Eye Chili) and Capsicum chinense (Yellow Lantern Chili), Respectively.

Gan HY, Gan HM, Savka MA, Triassi AJ, Wheatley MS, Naqvi KF, Foxhall TE, Anauo MJ, Baldwin ML, Burkhardt RN, O'Bryon IG, Dailey LK, Busairi NI, Keith RC, Khair MH, Rasul MZ, Rosdi NA, Mountzouros JR, Rhoads AC, Selochan MA, Tautanov TB, Polter SJ, Marks KD, Caraballo AA, Hudson AO.

Genome Announc. 2015 Apr 16;3(2). pii: e00288-15. doi: 10.1128/genomeA.00288-15.

39.

Evaporation-based microfluidic production of oil-free cell-containing hydrogel particles.

Fan R, Naqvi K, Patel K, Sun J, Wan J.

Biomicrofluidics. 2015 Mar 27;9(5):052602. doi: 10.1063/1.4916508. eCollection 2015 Sep.

40.

Ovarian dermoid causing pilimiction.

Naqvi KZ, Abdullah A, Jabeen M, Iqbal F, Edhi M.

J Coll Physicians Surg Pak. 2015 Jan;25(1):71-2. doi: 01.2015/JCPSP.7172.

PMID:
25604374
41.

Comorbidities predict worse prognosis in patients with primary myelofibrosis.

Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S.

Cancer. 2014 Oct 1;120(19):2996-3002. doi: 10.1002/cncr.28857. Epub 2014 Jun 10.

42.

The inter-monomer interface of the major light-harvesting chlorophyll a/b complexes of photosystem II (LHCII) influences the chlorophyll triplet distribution.

Zhang L, Melø TB, Li H, Naqvi KR, Yang C.

J Plant Physiol. 2014 Mar 1;171(5):42-8. doi: 10.1016/j.jplph.2013.11.008. Epub 2013 Dec 14.

PMID:
24484957
43.

Formation of self-inhibiting copper(II) nanoparticles in an autocatalytic Fenton-like reaction.

Naqvi KR, Marsh J, Chechik V.

Dalton Trans. 2014 Mar 28;43(12):4745-51. doi: 10.1039/c3dt53617c.

PMID:
24472897
44.

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.

Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2014 May;89(5):509-16. doi: 10.1002/ajh.23675. Epub 2014 Feb 21.

45.

The horror of unsafe abortion: case report of a life threatening complication in a 29-year old woman.

Naqvi KZ, Edhi MM.

Patient Saf Surg. 2013 Oct 16;7(1):33. doi: 10.1186/1754-9493-7-33.

46.

Pulsed-source time-resolved phosphorimetry: comparison of a commercial gated photomultiplier with a specially wired ungated photomultiplier.

Persvik Ø, Melø TB, Naqvi KR.

Photochem Photobiol Sci. 2013 Jun;12(6):1110-3. doi: 10.1039/c3pp50050k. Epub 2013 Mar 15.

PMID:
23503741
47.

Model for conformational relaxation of flexible conjugated polymers: application to p-phenylenevinylene trimers in nonpolar solvents.

Galvão AM, Di Paolo RE, Maçanita AL, Naqvi KR.

Chemphyschem. 2013 Feb 25;14(3):583-90. doi: 10.1002/cphc.201200869. Epub 2013 Jan 31.

PMID:
23364935
48.

The role of chelants in controlling Cu(II)-induced radical chemistry in oxidative hair colouring products.

Naqvi KR, Marsh JM, Godfrey S, Davis MG, Flagler MJ, Hao J, Chechik V.

Int J Cosmet Sci. 2013 Feb;35(1):41-9. doi: 10.1111/j.1468-2494.2012.00755.x. Epub 2012 Sep 26.

PMID:
22950483
49.

Publishing: Careless linking of Wallace and Darwin.

Naqvi KR.

Nature. 2012 May 23;485(7399):446. doi: 10.1038/485446c. No abstract available.

PMID:
22622558
50.

Three-level quality assessment of a dental hospital using EFQM.

Vakani F, Fatmi Z, Naqvi K.

Int J Health Care Qual Assur. 2011;24(8):582-91.

PMID:
22204263

Supplemental Content

Support Center